Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, Tuscan Regional Centre of Pharmacovigilance and Phytovigilance, University of Florence, Viale G. Pieraccini, 6, 50139, Florence, Italy.
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Syst Rev. 2020 Jan 24;9(1):19. doi: 10.1186/s13643-020-1280-5.
Products containing anthraquinones (AQ) are mainly used as laxatives and have several biological effects. Long-term use of AQ laxatives is associated with an increased risk of serious adverse events (AEs), such as colorectal cancer (CRC). We will systematically synthesize the evidence on the potential association between the use of AQ laxatives and the risk of CRC.
We will search MEDLINE, Embase, Scopus, the Cochrane Library, Google Scholar, and Clinicaltrials.gov. To avoid missing any relevant studies, we will search the bibliographies of retrieved papers and recent reviews in the field. Interventions will include products containing oral AQ laxatives, in particular, those derived from rhubarb, senna, cascara, buckhorn, and aloe. Two review authors will independently screen title, abstract, and full texts and will independently extract data from included studies. The primary outcome is the number of participants diagnosed with CRC, while the secondary outcome will be cases of melanosis coli. We will also consider all other AEs reported in the included studies, in particular, intestinal bleeding, alterations of gastrointestinal motility, and potential for dependence. When possible and appropriate, for each outcome, a meta-analysis will be performed.
This protocol is prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols guidelines. The protocol gives an insight into the scope and parameters for the systematic review to be carried out.
PROSPERO CRD42019125414.
含蒽醌类(AQ)的产品主要用作泻药,具有多种生物学作用。长期使用 AQ 类泻药与严重不良事件(AE)风险增加相关,例如结直肠癌(CRC)。我们将系统地综合蒽醌类泻药使用与 CRC 风险之间潜在关联的证据。
我们将检索 MEDLINE、Embase、Scopus、Cochrane 图书馆、Google Scholar 和 Clinicaltrials.gov。为避免遗漏任何相关研究,我们将检索检索到的论文和该领域近期综述的参考文献。干预措施将包括含有口服 AQ 类泻药的产品,特别是来源于大黄、番泻叶、鼠李皮、羊角拗和芦荟的产品。两名综述作者将独立筛选标题、摘要和全文,并独立从纳入研究中提取数据。主要结局是诊断为 CRC 的参与者人数,次要结局将是结肠黑变病的病例。我们还将考虑纳入研究中报告的所有其他 AE,特别是肠道出血、胃肠道动力改变和潜在依赖性。如有可能和适当,将对每个结局进行荟萃分析。
本方案是根据系统评价和荟萃分析首选报告项目的建议制定的。该方案深入了解了即将进行的系统评价的范围和参数。
PROSPERO CRD42019125414。